Cargando…
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
Psoriasis is a chronic, immune-mediated inflammatory disease with a worldwide prevalence ranging between 0.51 and 11.43%. It results in a large clinical and social burden, with patients frequently suffering from reduced quality of life, psychologic distress and debilitating comorbidities. Biologic a...
Autores principales: | Girolomoni, Giampiero, Savage, Laura, Gisondi, Paolo, Svensson, Åke, Mahé, Emmanuel, Augustin, Matthias, Puig, Luis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539267/ https://www.ncbi.nlm.nih.gov/pubmed/37710078 http://dx.doi.org/10.1007/s13555-023-01014-x |
Ejemplares similares
-
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016) -
Treatment Approaches to Moderate to Severe Psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2017) -
Management of Moderate to Severe Psoriasis in Patients with Metabolic Comorbidities
por: Gisondi, Paolo, et al.
Publicado: (2015) -
The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments
por: Gisondi, Paolo, et al.
Publicado: (2020) -
Glomerular filtration rate in patients with psoriasis treated with etanercept
por: Gisondi, Paolo, et al.
Publicado: (2016)